1. Building Trust in RWE Will Support Clearer Regulatory Uses

   • Gregory Daniel

   Editorial 23 December 2019 Pages: 417 - 419

2. A Transitional Probability Model for Parkinson’s Disease Motor States With Applications to Missing Data

   • Phillip Dinh

   Biostatistics: Statistics 23 December 2019 Pages: 420 - 425

3. Measurement Equivalence of Patient-Reported Outcome Measures Migrated to Electronic Formats: A Review of Evidence and Recommendations for Clinical Trials and Bring Your Own Device

   • Bill Byrom
   • Chad Gwaltney
   • Willie Muehlhausen

   Clinical Trials: Commentary 23 December 2019 Pages: 426 - 430

4. Training on the Use of Technology to Collect Patient-Reported Outcome Data Electronically in Clinical Trials: Best Practice Recommendations from the ePRO Consortium

   • Jenny J. Ly
   • Mabel Crescioni
   • ePRO Consortium

   Clinical Trials: Commentary 23 December 2019 Pages: 431 - 440

5. Best Practices for Avoiding Paper Backup When Implementing Electronic Approaches to Patient-Reported Outcome Data Collection in Clinical Trials

   • Cindy Howry
   • Celeste A. Elash
   • Tracey Rothrock

   Clinical Trials: Analytical Report 23 December 2019 Pages: 441 - 445

6. Comparison of Postdoctoral Pharmacy Training Programs: Drug Information Residencies and Medical Information Fellowships

   • Jimmy Gonzalez
   • Samantha Bryant
   • Evelyn R. Hermes-DeSantis

   Educational Perspective: Review Article 23 December 2019 Pages: 446 - 454

7. Age-Appropriate Pediatric Dosage Forms in Japan: Insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation

   • Jumpei Saito
   • Miki Akabane
   • Yoichi Ishikawa

   Global Perspectives: Original Article 23 December 2019 Pages: 455 - 471

8. Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective

   • Kaori Kido
   • Naoki Matsumaru
   • Katsura Tsukamoto

   Global Perspectives: Original Article 23 December 2019 Pages: 472 - 480

9. Technology Forecasting for Medical Devices Guidance Formulation: A Case Study in Japan

   • Sayaka Itoh
   • Shingo Kano

   Global Perspectives: Analytical Report Open access 23 December 2019 Pages: 481 - 489

10. The Use of Microblog “Weibo” by Chinese Patent Medicine Companies in China

    • Qirui Song
    • Carolina Oi Lam Ung
    • Hao Hu

    Global Perspectives: Original Article 23 December 2019 Pages: 490 - 496

11. Regulatory Trends in Drug Development in Asia Pacific

    • Fengyun Vicky Han
    • Karen Weiss

    Global Perspectives: Review Article 23 December 2019 Pages: 497 - 501

12. Benefits and Risks of Nonsteroidal Anti-inflammatory Drugs: Methodologic Limitations Lead to Clinical Uncertainties

    • Manas A. Rane
    • Jennifer G. Foster
    • Charles H. Hennekens

    Product Safety: Commentary 23 December 2019 Pages: 502 - 505

13. The Information for the Dosing of Medicinal Products in Different Age Intervals Is Ambiguous

    • Nika Zidarič
    • Samo Kreft

    Product Safety: Original Article 23 December 2019 Pages: 506 - 511

14. Risk-Based Monitoring: Key Conditions in Collaboration Between Contract Research Organization and Sponsor

    • Marion Wolfs
    • Amy Bambic
    • Sina Djali

    Regulatory Science: Original Article 23 December 2019 Pages: 512 - 518

15. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

    • David G. Strauss
    • Gary Gintant
    • Philip T. Sager

    Regulatory Science: Meeting Report 23 December 2019 Pages: 519 - 525

16. Of Straws, Camels, Research Regulation, and IRBs

    • Phoebe Friesen
    • Barbara Redman
    • Arthur Caplan

    Regulatory Science: Review Article 23 December 2019 Pages: 526 - 534

17. Future Perspectives for the Treatment of Diabetes: Importance of a Regulatory Framework

    • Katsura Tsukamoto
    • Miriam Cnop
    • Naoki Matsumaru

    Regulatory Science: Original Article 23 December 2019 Pages: 535 - 541

18. Managing the Risks of Medicines: An Examination of FDA’s Application of Criteria for Requiring a REMS

    • Paul J. Seligman
    • Rebekah H. Anguiano
    • Katie Stabi

    Regulatory Science: Original Article 23 December 2019 Pages: 542 - 548

19. Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy

    • Donatas Stakišaitis
    • Kristina Zamarytė-Sakavičienė
    • Rimas Jonas Jankūnas

    Value & Access: Original Article 23 December 2019 Pages: 549 - 553